Nova Scotia vowed to stop spending in the U.S. Here's how that's going
In February the province said it would "limit access" to provincial procurement for American businesses.
Last week the province made data available to CBC News showing a breakdown of public tenders since last November by the winning vendor's location.
Out of 1,226 tenders awarded between Nov. 1, 2024, and June 19, 2025, 966 of them — or about 79 per cent — went to companies that said they were based in Nova Scotia.
Twelve per cent, or 146 tenders, went to Ontario companies.
Companies based in the United States were awarded 21 tenders — just under two per cent.
One tender was awarded to a company based in Berlin.
Contracts include hospital food, pump track
Of the 21 contracts that went to suppliers based in the U.S., the largest was for just over $1 million to Sara Lee Frozen Bakery of Illinois, to supply food for health-care facilities starting in April 2025.
That contract was procured by a group purchasing body that works for hospitals across Canada.
Some other examples of public tenders that went to American companies included $539,000 to a Colorado firm to provide short-term rental compliance and monitoring services to the Department of Municipal Affairs and Housing, and a Halifax contract worth $535,000 for a Missouri company to design and build a pump track for cycling in Bedford.
In April, the province told CBC it had backed away from 11 contracts worth about $130,000. However, Premier Tim Houston defended sticking with an American company that was awarded a $70-million contract to work on the Macdonald bridge spanning Halifax harbour, saying there is no local option to do the work.
MORE TOP STORIES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Kevin O'Leary Put $8.5 million Into His ‘Shark Tank' Investments — How Much Did He Make?
Entrepreneur and investor Kevin O'Leary is probably most well known as one of the investors on 'Shark Tank.' You know, the show, where he and other investors listen to pitches from entrepreneurs and decide whether to put money towards their ventures. Check Out: For You: According to The Street, O'Leary has invested at least $8.5 million in around 40 companies since he's been on the show for about 16 years. Although it's hard to tell how much he's made in total out of all his 'Shark Tank' investments, there have been some businesses that have fared better than others — let's check them out. What Are O'Leary's Most Successful Investments on 'Shark Tank'? In 2013, Wicked Good Cupcakes appeared on 'Shark Tank' and O'Leary invested $75,000 in the company. In return, he wanted to be paid $1 per cupcake until his initial investment was paid back, then 45 cents for each one afterwards. Several years later, Wicked Good Cupcakes made $10 million in total sales, according to Food Republic. O'Leary was there to hand out the millionth cupcake sold. It's safe to say that he more than recouped his investment. Trending Now: O'Leary also invested in Basepaws in 2019 that earned him a massive profit, per Yahoo Finance. He invested $125,000 in the company in exchange for a 5% stake and the whole company was valued at $2.5 million. O'Leary has publicly said that, percentage-wise, Basepaws has been his biggest win so far. The company has reportedly been sold for around $50 million, which could mean that O'Leary earned about $2.5 million from the sale. Other companies he invested in, Shutterfly and Plated, have since sold for tens of millions of dollars. Safe to say that O'Leary made millions on these deals. How Much Has O'Leary Made? We probably won't know exactly how much O'Leary has made from all of his deals from 'Shark Tank,' since he's had to sign many nondisclosure agreements that prevent him from doing so. Despite losing half a million on one deal and probably more if you include other deals, this 'Shark Tank' investor is still probably coming up on top. Is it safe to say he earned more than the $8.5 million he's invested? Probably, but only O'Leary and his accountant will know for sure. What we do know is that O'Leary doesn't put all of eggs in one basket. At any time, he probably has around 30 to 40 companies in his private investment portfolio to spread out his risk, according to CNBC. A good percentage of these companies are probably going through the acquisition process and at that time, is probably when O'Leary will be able to know how much his investments have paid off. More From GOBankingRates 10 Cars That Outlast the Average Vehicle This article originally appeared on Kevin O'Leary Put $8.5 million Into His 'Shark Tank' Investments — How Much Did He Make? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
6 Ways To Make Yourself Richer With the Last Paycheck of the Year
Your last paycheck of the year might feel like nothing special, but you can actually use it as an opportunity to improve your financial life. Discover More: For You: Not only does it come at the perfect time for a financial review, getting income before the end of the year also allows you to make some moves before the calendar turns over. Here are some steps you can take to make yourself richer with the last paycheck of the year. Maximize Year-End Retirement Plan Contributions An important move to make before the end of December is to contribute as much as you can to your employer's retirement plan. While some tax-advantaged accounts, such as IRAs and HSAs, allow for contributions all the way up until your tax-filing deadline, you can only put money into 401(k) plan and 403(b) plans until the end of the calendar year. Your final paycheck is your last chance to boost your contribution before the new year starts — and the more you can sock away in your tax-advantaged retirement plans, the more likely you are to end up richer over the long run, thanks to both tax savings and compound growth. Trending Now: Upskill Yourself Many wealthy individuals, including the sixth-richest person on Earth, Warren Buffett, say that the best investment you can ever make is in yourself. When you get your last paycheck — particularly if it includes a bonus — it can be a good time to spend that money on upskilling yourself. Consider using some of that money to enroll in educational courses or workshops that can either broaden your skill set or deepen it. By improving your marketability, your investment can significantly boost your lifelong earnings. Review Your Investments The end of the year is a traditional time for investors to review their portfolios. When you get your last paycheck, first verify that the correct amount is being deducted to your savings and investment accounts. Then, review your portfolio as a whole. It's likely that your asset allocation is out of balance if you haven't made any changes since last year. If you intend to have 70% in stocks and 30% in bonds, for example, by year-end you might find that balance may now be closer to 60/40, or even 50/50. To keep your portfolio with your intended risk and reward profile, you may have to make some year-end adjustments. Analyze Your Budget Once your final paycheck arrives, you'll finally have a full year's worth of income and expenses in the books. This is a great time to look back and analyze your budget. Were you able to live within your means? Did you save and invest as much as you intended? What changes should you make for the coming year to ensure that you remain under-budget and up your financial gain to get out of debt and boost your savings? All of this data is available once you wrap up the year with your final paycheck. Performing this type of financial analysis can help boost your net worth in the coming year. Save and/or Invest Your Bonus Many year-end paychecks come with an annual bonus. This offers you an excellent opportunity to boost your savings and investments without much effort at all. As your bonus is by definition 'extra' money, it won't feel like it comes out of your pocket if you simply divert it to your savings and investments. Many experts recommend investing all sources of 'found' or 'free' money, such as year-end bonuses or tax returns, as you aren't relying on them to fund your day-to-day budget. Doing this every year can really pad your retirement nest egg. Pay Off Debt Regardless of the time of year, one of the best ways to improve your financial life is to pay off your high-interest debt. Typically, this comes in the form of credit card debt, which can charge annual interest rates of 25% or more. Diverting some of your year-end paycheck and/or bonus towards your high-interest debt can get you out of a financial hole before you dig yourself in any deeper, and that's a key step in the quest to make yourself richer. More From GOBankingRates Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy This article originally appeared on 6 Ways To Make Yourself Richer With the Last Paycheck of the Year Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET on July 24, 2025. After a thorough strategic review, the ReShape Board of Directors unanimously determined that a merger with Vyome Therapeutics, Inc. (Vyome), a private clinical-stage company targeting immuno-inflammatory and rare diseases, and a simultaneous sale of ReShape's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (together, Biorad), are advisable and in the best interests of ReShape and its stockholders. Additionally, the independent proxy advisory firms ISS and Glass Lewis both recently issued recommendations in favor of Proposals 1, 2 and 3. Addressing the Company's shareholders, Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, noted, 'Your vote is important, no matter how many or how few shares you may own, for ReShape to take the next step in its evolution as the merger agreement with Vyome and a concurrent asset purchase agreement with Biorad, will successfully maximize value for our stockholders.' We are asking that you vote FOR each of the proposals on the agenda, including Proposals 1, 2, and 3 related to (1) the issuance of shares of our common stock, (2) the approval of the sale of substantially all of ReShape's assets, and (3) amending our certificate of incorporation to implement the post-closing composition of our Board of Directors, each in connection with our transaction with Vyome. Additionally, we are grateful to our Series C preferred stockholders for substantially reducing their liquidation preference, enabling our common stockholders to better realize the potential value of the merger. I am truly excited about the value we are delivering to all of our stockholders and the significant growth potential these transactions will enable, once approved by our shareholders.' 'We believe this transaction will allow us to unlock the full potential of Vyome's pipeline by focusing on advancing the development of the combined company's immune-inflammatory assets and identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market,' stated Venkat Nelabhotla, Chief Executive Officer and Co-Founder of Vyome. "Vyome aims to build a world-class company by combining top talent and capital from the U.S. and India to develop cost-efficient therapies for chronic immune-inflammatory diseases. We also plan to expand our portfolio across biopharma, medical devices, and healthcare AI. With no debt and a clean capital structure, we believe Vyome is well-positioned for public market success.' To successfully execute ReShape's transformation, it is imperative that stockholders vote in favor of each proxy proposal on the agenda. The proposals - including Proposals 1, 2, and 3 – would approve: 1. The issuance of shares of ReShape common stock in connection with the transaction.2. The sale of substantially all of ReShape's assets to Biorad. 3. Certain amendments to ReShape's certificate of incorporation to facilitate the proposed post-closing board composition of the company. Those who have not voted should vote today. Those who voted against Proposals 1, 2, or 3 are asked to please reconsider their votes based on the factors described in this press release. The proxy statement for the Special Meeting of Stockholders of ReShape filed on June 24, 2025 contains important information and this press release should be read in conjunction with the proxy statement, which, along with other relevant materials, is available at no charge at the U.S. Securities and Exchange Commission's website and at the Company's website Shareholders can vote by telephone, or the follow the easy instructions on the proxy card or voting instruction form previously sent. For any questions or assistance in voting shares, please call our proxy solicitor, INNISFREE M&A INCORPORATEDTOLL-FREE, at 1-877-750-8310. About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immune-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker 'HIND' pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025. To learn more, please visit About Biorad MedisysBiorad Medisys Pvt. Ltd.® is a rapidly growing med-tech company dedicated to redefining healthcare standards with precision-engineered medical devices backed by rigorous scientific research. It operates three business units – Indovasive, Orthovasive and Neurovasive. Indovasive offers consumables and equipment in Urology and Gastroenterology. The Orthovasive segment sells a complete range of Knee and Hip implants for both Primary and Revision surgeries. It has recently forayed into Neurovascular BU for selling a wide portfolio of products in peripheral vascular, neurovascular and rehabilitation segments. It has two manufacturing facilities in India and is currently exporting to 50+ countries. To realize its global expansion strategy, it recently acquired a Swiss based company, Marflow, which specializes in commercialization of products in Urology & Gastroenterology. About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit Forward-Looking Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. Additional Information In connection with the proposed merger with Vyome (the 'Merger') and sale of assets to Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd. (the 'Asset Sale'), ReShape filed with the SEC on June 24, 2025 and mailed or otherwise provided to its stockholders the joint proxy statement/prospectus (the 'joint proxy statement/prospectus') and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape's stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety because they contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials and other documents filed by ReShape with the SEC at the SEC's website at at ReShape's website at or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary. CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
